The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 23, 2020

Filed:

Feb. 29, 2016
Applicants:

Mission Therapeutics Limited, Cambridge, GB;

Cambridge Enterprise Limited, Cambridge, GB;

Inventors:

Xavier Jacq, Cambridge, GB;

Helen Robinson, Cambridge, GB;

Yaara Ofir-Rosenfeld, Cambridge, GB;

Stephen Jackson, Cambridge, GB;

Paul Wijnhoven, Cambridge, GB;

Ryotaro Nishi, Cambridge, GB;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C07H 21/02 (2006.01); C07H 21/04 (2006.01); A61K 48/00 (2006.01); G01N 33/50 (2006.01); A61K 31/4745 (2006.01); A61K 31/502 (2006.01); A61K 31/7048 (2006.01); A61K 41/00 (2020.01); C12Q 1/6886 (2018.01); C12N 9/64 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5008 (2013.01); A61K 31/4745 (2013.01); A61K 31/502 (2013.01); A61K 31/7048 (2013.01); A61K 41/0038 (2013.01); C12N 9/6472 (2013.01); C12Q 1/6886 (2013.01); A61K 2039/505 (2013.01); C12Q 2600/106 (2013.01); G01N 2333/948 (2013.01); G01N 2500/02 (2013.01);
Abstract

The present application relates to materials and methods for exploiting synthetic lethality and/or chemo-sensitisation in DNA damage response (DDR) pathways. In particular, the application relates to ubiquitin hydrolase protein Ubiquitin Specific Protease 4 (USP4) and its association with DDR pathways. Further, the use of USP4 inhibitors in the treatment of cancer and methods of screening is described, in particular, use of inhibitors of USP4 in the treatment of tumours defective in double-strand break repair (DSBR) and/or tumours resistant to platinum-based chemotherapy, or to sensitise, i.e. chemosensitise or radiosensitise tumours to other therapeutic agents.


Find Patent Forward Citations

Loading…